BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1385 related articles for article (PubMed ID: 16158053)

  • 21. Requirement of a specific Sp1 site for histone deacetylase-mediated repression of transforming growth factor beta Type II receptor expression in human pancreatic cancer cells.
    Zhao S; Venkatasubbarao K; Li S; Freeman JW
    Cancer Res; 2003 May; 63(10):2624-30. PubMed ID: 12750289
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effects of trichostatin A, a histone deacetylase inhibitor, on the regulation of apoptosis in H-ras-transformed breast epithelial cells.
    Park H; Lee YJ; Kim TH; Lee J; Yoon S; Choi WS; Myung CS; Kim HS
    Int J Mol Med; 2008 Nov; 22(5):605-11. PubMed ID: 18949380
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Characterization of an E2F1-specific binding domain in pRB and its implications for apoptotic regulation.
    Julian LM; Palander O; Seifried LA; Foster JE; Dick FA
    Oncogene; 2008 Mar; 27(11):1572-9. PubMed ID: 17891180
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Retinoblastoma protein represses transcription by recruiting a histone deacetylase.
    Magnaghi-Jaulin L; Groisman R; Naguibneva I; Robin P; Lorain S; Le Villain JP; Troalen F; Trouche D; Harel-Bellan A
    Nature; 1998 Feb; 391(6667):601-5. PubMed ID: 9468140
    [TBL] [Abstract][Full Text] [Related]  

  • 25. DNMT1 forms a complex with Rb, E2F1 and HDAC1 and represses transcription from E2F-responsive promoters.
    Robertson KD; Ait-Si-Ali S; Yokochi T; Wade PA; Jones PL; Wolffe AP
    Nat Genet; 2000 Jul; 25(3):338-42. PubMed ID: 10888886
    [TBL] [Abstract][Full Text] [Related]  

  • 26. HDAC inhibitors TSA and sodium butyrate enhanced the human IL-5 expression by altering histone acetylation status at its promoter region.
    Han S; Lu J; Zhang Y; Cheng C; Li L; Han L; Huang B
    Immunol Lett; 2007 Feb; 108(2):143-50. PubMed ID: 17270283
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A Ras homologue member I directly inhibits signal transducers and activators of transcription 3 translocation and activity in human breast and ovarian cancer cells.
    Nishimoto A; Yu Y; Lu Z; Mao X; Ren Z; Watowich SS; Mills GB; Liao WS; Chen X; Bast RC; Luo RZ
    Cancer Res; 2005 Aug; 65(15):6701-10. PubMed ID: 16061651
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Loss of NECL1, a novel tumor suppressor, can be restored in glioma by HDAC inhibitor-Trichostatin A through Sp1 binding site.
    Gao J; Chen T; Liu J; Liu W; Hu G; Guo X; Yin B; Gong Y; Zhao J; Qiang B; Yuan J; Peng X
    Glia; 2009 Jul; 57(9):989-99. PubMed ID: 19062177
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Hydroxychloroquine, chloroquine, and all-trans retinoic acid regulate growth, survival, and histone acetylation in breast cancer cells.
    Rahim R; Strobl JS
    Anticancer Drugs; 2009 Sep; 20(8):736-45. PubMed ID: 19584707
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Histone modification in the TGFbetaRII gene promoter and its significance for responsiveness to HDAC inhibitor in lung cancer cell lines.
    Osada H; Tatematsu Y; Sugito N; Horio Y; Takahashi T
    Mol Carcinog; 2005 Dec; 44(4):233-41. PubMed ID: 16163707
    [TBL] [Abstract][Full Text] [Related]  

  • 31. E2F-like elements in p27(Kip1) promoter specifically sense deregulated E2F activity.
    Ozono E; Komori H; Iwanaga R; Ikeda MA; Iseki S; Ohtani K
    Genes Cells; 2009 Jan; 14(1):89-99. PubMed ID: 19077036
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Biochemistry and biology of ARHI (DIRAS3), an imprinted tumor suppressor gene whose expression is lost in ovarian and breast cancers.
    Yu Y; Luo R; Lu Z; Wei Feng W; Badgwell D; Issa JP; Rosen DG; Liu J; Bast RC
    Methods Enzymol; 2006; 407():455-68. PubMed ID: 16757345
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Differences in DNA binding properties between E2F1 and E2F4 specify repression of the Mcl-1 promoter.
    Croxton R; Ma Y; Cress WD
    Oncogene; 2002 Feb; 21(10):1563-70. PubMed ID: 11896585
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Histone deacetylase inhibitor apicidin downregulates DNA methyltransferase 1 expression and induces repressive histone modifications via recruitment of corepressor complex to promoter region in human cervix cancer cells.
    You JS; Kang JK; Lee EK; Lee JC; Lee SH; Jeon YJ; Koh DH; Ahn SH; Seo DW; Lee HY; Cho EJ; Han JW
    Oncogene; 2008 Feb; 27(10):1376-86. PubMed ID: 17828306
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The p107 tumor suppressor induces stable E2F DNA binding to repress target promoters.
    O'Connor RJ; Schaley JE; Feeney G; Hearing P
    Oncogene; 2001 Apr; 20(15):1882-91. PubMed ID: 11313936
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Interleukin-8 expression is regulated by histone deacetylases through the nuclear factor-kappaB pathway in breast cancer.
    Chavey C; Mühlbauer M; Bossard C; Freund A; Durand S; Jorgensen C; Jobin C; Lazennec G
    Mol Pharmacol; 2008 Nov; 74(5):1359-66. PubMed ID: 18669446
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Transcriptional repression of the E2F-1 gene by interferon-alpha is mediated through induction of E2F-4/pRB and E2F-4/p130 complexes.
    Furukawa Y; Iwase S; Kikuchi J; Nakamura M; Yamada H; Matsuda M
    Oncogene; 1999 Mar; 18(11):2003-14. PubMed ID: 10208422
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Promoter specific sensitivity to inhibition of histone deacetylases: implications for hormonal gene control, cellular differentiation and cancer.
    Dressel U; Renkawitz R; Baniahmad A
    Anticancer Res; 2000; 20(2A):1017-22. PubMed ID: 10810390
    [TBL] [Abstract][Full Text] [Related]  

  • 39. E2F sites in the Op18 promoter are required for high level of expression in the human prostate carcinoma cell line PC-3-M.
    Polzin RG; Benlhabib H; Trepel J; Herrera JE
    Gene; 2004 Oct; 341():209-18. PubMed ID: 15474303
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Role of retinoblastoma protein and E2F-1 transcription factor in the acquisition of 5-fluorouracil resistance by colon cancer cells.
    Obama K; Kanai M; Kawai Y; Fukushima M; Takabayashi A
    Int J Oncol; 2002 Aug; 21(2):309-14. PubMed ID: 12118326
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 70.